- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| Mo | GRI Bio, Inc.: GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds | 59 | - Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI... ► Artikel lesen | ||
| Mo | Crazy Woman Creek Bancorp, Inc.: Crazy Woman Creek Bancorp Reports Earnings for Fiscal Year 2024; Declares Annual Cash Dividend of $0.32 Per Share | 55 | BUFFALO, Wyo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- We continue to build our franchise as Crazy Woman Creek Bancorp (OTCPink: CRZY) and Buffalo Federal Bank, known as The Banks of Buffalo, Sheridan,... ► Artikel lesen | ||
| Mo | TX Rail Products, Inc. Reports Revenue Growth of 16% for Fiscal 2024 | 62 | ASHLAND, Ky., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TX Rail Products, Inc. (OTC Markets PINK: TXRP), a supplier of rail and rail products to the U.S. coal mining industry, short line railroads and tunneling... ► Artikel lesen | ||
| Mo | Marel hf.: Board requests to delist shares from Nasdaq Iceland and Euronext Amsterdam | 166 | At its meeting today, the Board of Directors of Marel hf. approved to request the delisting of Marel shares from Nasdaq Iceland hf. (Nasdaq Iceland) and Euronext Amsterdam as soon as permitted and reasonably... ► Artikel lesen | ||
| Mo | OptimizeRx Corporation: OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO | 74 | WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage... ► Artikel lesen | ||
| Mo | Navient Corporation: Navient to sell Government Services business to Gallant Capital | 79 | HERNDON, Va., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI) announced today that it has reached an agreement to sell its Government Services business to an affiliate of Gallant Capital... ► Artikel lesen | ||
| Mo | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement | 95 | Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction... ► Artikel lesen | ||
| Mo | Foremost Clean Energy Ltd.: Foremost Clean Energy Announces Approval of the Winston Gold and Silver Spin-Out and Additional Results from AGSM | 105 | Immediately prior to the closing (the "Effective Date"), all Foremost shareholders are expected to receive two shares of Rio Grande for every one share of Foremost they hold VANCOUVER, British Columbia... ► Artikel lesen | ||
| Mo | Singular Genomics Systems, Inc.: Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share | 579 | SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC) ("Singular Genomics" or the "Company"), a company leveraging novel next-generation sequencing (NGS) and... ► Artikel lesen | ||
| Mo | Vivos Inc. Announces Launch of Groundbreaking RadioGel Precision Radionuclide Therapy Human Clinical Trial | 57 | Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- - Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy in India.... ► Artikel lesen | ||
| Mo | Wave Life Sciences USA, Inc.: Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity | 50 | WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or... ► Artikel lesen | ||
| Mo | Reliance Global Group, Inc.: Reliance Global Group Reflects on a Transformative Year and Looks Ahead to 2025 | 75 | OneFirm Approach Delivering Results - Drives Increased Revenue, Reduced Expenses, and Growing EBITDA Spetner Acquisition Nears Final Stages, Strengthening Company's Future Prospects LAKEWOOD, N.J.... ► Artikel lesen | ||
| Mo | Stran & Company, Inc.: Stran & Company Reports Preliminary Selected Unaudited Results for the Nine Months Ended September 30, 2024 | 71 | Completed acquisition of strategic assets of Gander Group Revenue expected to grow approximately 7.8% compared to the first nine months of 2023 Quincy, MA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Stran... ► Artikel lesen | ||
| Mo | HCW Biologics, Inc: HCW Biologics Inc. Received NASDAQ Staff Determination Letter | 58 | Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE... ► Artikel lesen | ||
| Mo | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | 76 | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | ||
| Mo | Spectral AI, Inc.: Spectral AI Announces Confirmation of Compliance of its Nasdaq Listing Requirements | 68 | DALLAS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from... ► Artikel lesen | ||
| Mo | iLearningEngines Holdings, Inc.: iLearningEngines Voluntarily Initiates Chapter 11 Proceedings | 108 | BETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- iLearningEngines, Inc. (NASDAQ: AILE) ("iLearningEngines," "ILE" or the "Company"), a leader in AI-powered learning and work automation, today announced... ► Artikel lesen | ||
| Mo | APA Corporation Announces Results of Private Exchange Offers, Tender Offers, and Consent Solicitations at Extended Early Consent Date and Upsizing of Tender Offers | 104 | HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- APA Corporation ("APA") (Nasdaq: APA) announced today the extended early results as of 5:00 p.m., New York City time, on December 20, 2024 (the "Extended... ► Artikel lesen | ||
| Mo | Osisko Gold Royalties Ltd.: Osisko Announces Acquisition of Additional Gibraltar Silver Stream Interest and Closing of the Dalgaranga Royalties Acquisition | 85 | MONTRÉAL, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd ("Osisko" or the "Company") (OR: TSX & NYSE) is pleased to announce that it has completed an amendment to its silver stream (the... ► Artikel lesen | ||
| Mo | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | 85 | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | ||
| Mo | NextGen Digital Platforms Inc.: NextGen Digital Announces Listing on Frankfurt Stock Exchange | 173 | Fredericton, New Brunswick, Dec. 23, 2024 (GLOBE NEWSWIRE) -- NextGen Digital Platforms Inc. (CSE:NXT) (FSE:Z12) ("NextGen" or the "Company") is pleased to announce that the Company's shares have... ► Artikel lesen | ||
| Mo | NewGenIVF Group Limited: NewGen Progresses Reverse Merger Plans with Engagement of Legal Teams and Updated Timeline | 275 | BANGKOK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) ("NewGen" or the "Company") today announced that both parties involved in the previously announced reverse merger... ► Artikel lesen | ||
| Mo | VYNE Therapeutics Inc.: VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor | 62 | Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable... ► Artikel lesen | ||
| Mo | Gain Therapeutics, Inc.: Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease | 47 | The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months... ► Artikel lesen | ||
| Mo | Psyence Biomedical Ltd.: Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements | 86 | NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
